In the wake of a judge’s ruling that stripped ImClone Systems of key exclusive patent rights, the biotech’s biggest rival wasted little time taking advantage of the situation. After the market closed Tuesday, biotech giant Amgen Inc. said it had licensed the same technology to which ImClone lost its exclusive rights. Meanwhile, in what could lead to a full-blown power struggle, newly elected ImClone director Carl Icahn blasted management for the patent loss and for ImClone’s “sorry record” in general.
Popularity: 3% [?]
Posted on Friday, September 22nd, 2006. Filed under: Business Law, Law Misc
You can leave a response, or trackback from your own site.
Rate This Post - Vote Now!